促红细胞生成素不同给药次数对防治早产儿贫血的临床研究被引量：3

Erythropoietin in the prevention of the number of different administration clinical study of anemia in premature children

下载PDF

导出

摘要目的:探讨促红细胞生成素(EPO)防治早产儿贫血的最佳治疗方案。方法:将78例早产儿随机分为对照组,治疗1组和治疗2组,对照组口服维生素,治疗1组用EPO按750IU/(kg·周),分4次皮下注射,治疗2组用EPO按750IU/(kg·周),分2次皮下注射,动态观察患者的血色素、网织红细胞比例、血清铁蛋白变化,记录输血次数,相关数据进行统计学处理。结果:对照组与治疗组(治疗1组+治疗2组)比较,血红蛋白、网织红细胞比例、输血次数均存在显著差异,未见明显毒副作用,说明EPO对防治早产儿贫血安全、有效;治疗1组与治疗2组比较,血红蛋白、网织红细胞比例在治疗后期及输血次数的差异具有显著性,治疗1组优于治疗2组。结论:促红细胞生成素(EPO)在大剂量、早治疗的前提下,分多次给药对防治早产儿贫血疗效更好。 Objective：To investigate erythropoietin （EPO） prevention and treatment of anemia in premature children the best treatment regimens. Methods：78 patients with premature children will be randomly divided into control group,treatment group 1 and treatment 2 group and the control group was treated with vitamins,treatment group 1 with EPO by 750 IU/（kg·weeks）,4 times subcutaneously,treatment 2 group with EPO by 750 IU/（kg·weeks）,sub-2 subcutaneously,dynamic observation of hemoglobin,reticulocyte percentage,serum ferritin changes,record the number of blood transfusion,the data were analyzed statistically. Results：In control group and treatment group（treatment group 1＋treatment 2 group）,hemoglobin,reticulocyte percentage,the number of blood transfusion were significant differences,no significant side effects,indicating EPO on the prevention and treatment of anemia in premature children was safe and effective; treatment 1 comparison group and treatment group 2,hemoglobin,reticulocyte percentage and blood transfusion in the treatment of late the number of significant differences in the treatment group 1 than group 2 treatment. Conclusion：Erythropoietin（EPO） in large doses,early treatment of the subject,the prevention of preterm delivery in multiple child anemia better.

作者黄朝鸿李兵飞郑瑞庆

机构地区江西省赣州市妇女儿童医院

出处《中国当代医药》 2010年第26期36-37,共2页 China Modern Medicine

基金江西省赣州市卫生局科研课题

关键词早产儿促红细胞生成素贫血 Premature child Erythropoietin Anemia

分类号 R722.6 [医药卫生—儿科]

引文网络
相关文献

参考文献8

1李月梅.促红细胞生成素在早产儿贫血治疗中的研究进展[J].新生儿科杂志,2002,17(4):188-190. 被引量：23
2Donato H,Vain N,Rendo P,et al.Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants:results of a randomized,placbo-controlled,multicenter trial[J].Pediatries,2000,105(5):1066-1072.
3Pollak A,Hayde M,Hayn M,et al.Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants[J].Pediatrics,2001,107(1):78-85.
4Dame C,Fahnenstich H,Freitag P,et al.Erythropoietin mRNA expression in human fetal and neonatal tissue[J].Boold,1998,92:3218-3225.
5Kumar P,Shankaran S,Krishnan RG.Recombinant human erythropoietin therapy for treatment of anemia of premature in every low birth weight infants:a randomized,double-blind,placebo controlled trial[J].J Perinatol,1998,18(3):173-177.
6林泌姜洪杨秀玉.促红细胞生成素的临床研究进展.基础医学与临床,2002,16(4):147-148.
7常立文,刘皖君,廖财绪,赵锡慈.不同剂量重组人类促红细胞生成素防治早产儿贫血的疗效观察[J].中国实用儿科杂志,2000,15(12):740-742. 被引量：36
8Brown MS,Keith JF.Comparison between two and five doses a week of recombinant human erythropoietin for anemia of prematurity:a randomized tria[J].Pediatres Pediatries,1999,104(1):210-215.

二级参考文献29

1[1]Emmerson AJB,Coles Hjl,Stern CMM,et al.Double blind trial of recombinant human erythropoietin in preterm infants.Arch Dis Child,1993;68(3):291
2[2]Shannon KM,Keith ⅢJF，Mentzer WC,et al.Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very-low-birth-weight preterm infants.Pediatrics,1995;95(1):1
3[3]Messer J,Haddad J,Donato L,et al.Early treatment of premature infants with recombinant human erythropoietin.Pediatrics,1993;92(4):519
4[4]Soubasi V,Kremenopoulos G,Diamanti E,et al.Follow-up of very low-birth-weight infants after erythropoietin treatment to prevent anemia of prematurity.J Pediatr,1995;127(2):291
5[5]Carnielli V,Montini G,DaDioi R,et al.Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants.J Pediatr,1992;121(1):98
6[6]Shannon KM,Mentzer WC,Albels RI,et al.Recombinant human erythropoietin in the anemia of prematurity:results of a placebo controlled pilot study.J Pediatr,1991;118(6):949
7[7]Al-Kharfy A,Smyth JA,Wadsworth L,et al.Erythropoietin therapy in neonates at risk of having bronchopulmonary dysplasia and requiring multiple transfusions.J Pediatr,1996;129(1):89
8[8]Maier FF,Obladen M,Scigalla P,et al.The effect of epoetin beta(recombinant human erythopoietin)on the need for transfusion in very-low-birth-weight infants.N Engl J Med,1994;330(7):1173
9[9]Bechensteen AG,Haga P,Halvorsen S,et al.Effect of low and moderate doses of recombinant human erythropoietin on the haematological response in premature infant on a high protein and iron intake.Eur J Pediatr,1997;156(1):56
10[1]Reiter PD, Rosenberg AA, Valuck RJ. Factors associated with successful epoetin alfa therapy in premature infants. Ann Pharmacother, 2000,34:433-439.